Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansion of its Research and Development Arm
July 26 2022 - 8:30AM
Predictive Oncology (NASDAQ: POAI) today announced a strategic
move to further strengthen its business and product offerings by
appointing Julia Kirshner, Ph.D., as Chief Scientific Officer. Dr.
Kirshner currently serves as Senior Vice President at Predictive
Oncology and President of POAI’s zPREDICTA division and will be
elevated to the post beginning August 1, 2022.
In this newly created role, Dr. Kirshner will oversee the
scientific process for the entire suite of solutions POAI offers
for oncology drug development, ranging from early discovery to
clinical trials. Her responsibilities will include leading a
long-term vision for POAI’s product development strategy, driving
adoption of current POAI assets and guiding product iteration. She
will also be working closely with the board of directors to
establish a new scientific advisory board.
“Dr. Kirshner is a highly-qualified and well-respected
scientific leader who understands the core technical and commercial
value of each of the company’s product lines,” said J. Melville
Engle, Chief Executive Officer of Predictive Oncology. “She brings
the scientific experience and deep level of expertise to our
product development process that makes her the ideal candidate to
help guide, support and grow all our business units.”
Dr. Kirshner brings a strong scientific background to her new
position that includes both start-up and academic settings. She
founded zPREDICTA in 2014 and took it from a concept to
profitability. Predictive Oncology acquired zPREDICTA because of
Dr. Kirshner’s advancements in oncology drug development that
complemented POAI’s mission. Notably, Dr. Kirshner created
tumor-specific in vitro 3D models for drug development
that reconstruct tissue microenvironments and mimic drug
response.
Dr. Kirshner’s academic experience includes training at the City
of Hope National Medical Center, where she earned her Ph.D.,
Lawrence Berkeley National Lab, and the University of Alberta.
Subsequently, she joined the faculty at the Department of
Biological Sciences at Purdue University. While there, Dr.
Kirshner’s work was supported by competitive grants from major
government agencies. Her work has been published in top
peer-reviewed journals and she is a co-inventor on two granted
patents.
Dr. Kirshner’s role also includes overseeing the consolidation
of POAI’s TumorGenesis division, which will be moved to the
company’s flagship Pittsburgh location where POAI conducts its
artificial intelligence (AI) and lab functions. Serving as the hub
of POAI’s research and development arm, the Pittsburgh site will
additionally be expanding its lab space to meet the anticipated
growth needs.
“By consolidating and growing our research and development
capabilities, we will be better able to serve pharmaceutical and
biotech companies looking to bring more effective cancer treatments
to market,” noted Dr. Kirshner. “This Includes testing new
molecules and repurposing drugs for our clients that failed in
clinical trials.”
POAI expects the process to be completed by September 30, 2022.
Richard Gabriel, Senior Vice President of Research and Development
at Predictive Oncology and Site Leader for TumorGenesis, will stay
in his present role through that date to ensure a smooth
transition.
About Predictive OncologyPredictive Oncology
(NASDAQ: POAI) is a knowledge-driven company focused on applying
artificial intelligence (AI) to develop optimal cancer therapies,
which can lead to more effective treatments and improved patient
outcomes. Through AI, Predictive Oncology uses a database of
150,000+ cancer tumors, categorized by patient type, against drug
compounds to help the drug discovery process and increase the
probability of success. The company offers a suite of
solutions for oncology drug development from early discovery to
clinical trials.
Public Relations Contact:Predictive
OncologyTheresa
Ferguson630-566-2003tferguson@predictive-oncology.com
Investor Relations Contact:Landon Capital Keith
Pinder(404) 995-6671kpinder@landoncapital.net
Forward-Looking Statements:Certain matters
discussed in this release contain forward-looking statements. These
forward-looking statements reflect our current expectations and
projections about future events and are subject to substantial
risks, uncertainties and assumptions about our operations and the
investments we make. All statements, other than statements of
historical facts, included in this press release regarding our
strategy, future operations, future financial position, future
revenue and financial performance, projected costs, prospects,
changes in management, plans and objectives of management are
forward-looking statements. The words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Our actual future performance may
materially differ from that contemplated by the forward-looking
statements as a result of a variety of factors including, among
other things, factors discussed under the heading “Risk Factors” in
our filings with the SEC. Except as expressly required by law,
the Company disclaims any intent or obligation to update these
forward-looking statements.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/09b22a63-d158-4b3c-ae20-0bba4fc0409c
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024